| Symbol | MYCOF |
|---|---|
| Name | MYDECINE INNOVATIONS GROUP INC NEW |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | V6E 3C9 Canada BC Suite 1890 - 1075 West Georgia Street |
| Telephone | +1 604-687-2038 |
| Fax | — |
| — | |
| Website | https://www.mydecine.com |
| Incorporation | CA |
| Incorporated On | 2013 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | BF Borgers CPA PC; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Canadian Securities Exchange |
| CIK | 0000806175 |
| Description | Mydecine Innovations Group Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. It also develops MYCO-005, MYCO-006, and MYCO-007 for MDMA and psilocybin analogs. The company has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. Additional info from OTC: |
No news found.